Phase I Study of Alferon N Injection in Persons With Asymptomatic Human Immunodeficiency Virus (HIV) Infection

Inclusion Criteria Patients must have: * HIV-1 seropositivity. * CD4 count \> 400/mm3. * Eligibility for care in the military medical system. Prior Medication: Allowed: * Acyclovir. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * AIDS- or ARC-defining condition (unexplained weight loss, fever, diarrhea, night sweats). * Evidence of AIDS dementia. * Chronic hepatitis with severe liver dysfunction. * Active gastrointestinal, renal, respiratory, endocrine, hematologic, cardiovascular, or psychiatric disorder that would limit ability to complete the study. * Hemophilia. * Co-existent disease likely to result in death within the next 2 years. * Known hypersensitivity to human interferon alpha. * Known anaphylactic hypersensitivity to mouse immunoglobulin (IgG), egg protein, or neomycin. Concurrent Medication: Excluded: * Any other concurrent experimental medications. Patients with the following prior conditions are excluded: * History of AIDS- or ARC-defining condition (unexplained weight loss, fever, diarrhea, night sweats). * Evidence of chronic hepatitis with severe liver dysfunction. Prior Medication: Excluded within 5 days prior to study entry: * Immunosuppressive agents. * Chemotherapy. * Steroids. Excluded within 45 days prior to study entry: * BCG vaccine. * Isoprinosine. * Other immune modulators. Excluded within 3 months prior to study entry: * Any form of interferon. * Antiviral therapy. * Immunoregulatory therapy (other than acyclovir). 1\. Active drug abuse (narcotic or alcohol abuse documented within the past 6 months). * Unlikely or unable to comply with the requirements of the protocol.